ProPhase Labs, Inc. Notes Payable, Noncurrent
ProPhase Labs, Inc. (PRPH) had Notes Payable, Noncurrent of $7.22 million as of 2023-03-31, per its 10-Q filed 2023-05-12.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt, Excluding Current Maturities
us-gaap:LongTermNotesPayable · last filed 2023-05-12
- 2023-03-31: Notes Payable, Noncurrent $7.22M.
- 2022-12-31: Notes Payable, Noncurrent $0.00.
- 2022-03-31: Notes Payable, Noncurrent $18.00K.
- 2021-12-31: Notes Payable, Noncurrent $44.00K.
| Period end | Notes Payable, Noncurrent |
|---|---|
| 2023-03-31 | $7.22M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $0.00 10-Q · filed 2023-05-12 |
| 2022-03-31 | $18.00K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $44.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $81.00K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |